KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other financing activities (2016 - 2023)

Ionis Pharmaceuticals (IONS) has disclosed Other financing activities for 9 consecutive years, with $517000.0 as the latest value for Q3 2023.

  • For Q3 2023, Other financing activities fell 19.72% year-over-year to $517000.0; the TTM value through Dec 2024 reached $517000.0, down 72.75%, while the annual FY2025 figure was $18.9 million, N/A changed from the prior year.
  • Other financing activities hit $517000.0 in Q3 2023 for Ionis Pharmaceuticals, down from $736000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $15.3 million in Q1 2021 and bottomed at $367000.0 in Q2 2020.
  • Average Other financing activities over 5 years is $3.8 million, with a median of $690000.0 recorded in 2022.
  • Year-over-year, Other financing activities surged 1584.48% in 2019 and then crashed 90.84% in 2020.
  • Ionis Pharmaceuticals' Other financing activities stood at $401000.0 in 2019, then soared by 146.88% to $990000.0 in 2020, then grew by 21.21% to $1.2 million in 2021, then plummeted by 38.67% to $736000.0 in 2022, then fell by 29.76% to $517000.0 in 2023.
  • According to Business Quant data, Other financing activities over the past three periods came in at $517000.0, $736000.0, and $644000.0 for Q3 2023, Q4 2022, and Q3 2022 respectively.